Abstract
Purpose
The understanding of cognitive symptoms in patients with IDH-Mutant gliomas (IDH-Mut) is rapidly developing. In this article, we summarize the neuroscientific knowledge base regarding the influence of IDH-Mut tumors and their treatment on cognition and provide guidance regarding the management of these symptoms in patients.
Methods
We performed a review of peer reviewed publications relevant to IDH-Mut glioma and cognitive outcomes and provide an overview of the literature as well as a case example to clarify management strategies.
Results
At the time of presentation, patients with IDH-Mut gliomas have a favorable cognitive profile as compared with those with IDH-wild type (WT) tumors. The relatively low cognitive burden may reflect the slower growth rate of IDH-Mut tumors, which is less disruptive to both local and widespread neural networks. Human connectomic research using a variety of modalities has demonstrated relatively preserved network efficiency in patients with IDH-Mut gliomas as compared with IDH-WT tumors. Risk of cognitive decline from surgery can potentially be mitigated by careful integration of intra-operative mapping. Longer term cognitive risks of tumor treatment, including chemotherapy and radiation, are best managed by instituting neuropsychological assessment as part of the long-term care of patients with IDH-Mutant glioma. A specific timeline for such integrative care is provided.
Conclusions
Given the relative recency of the IDH-mutation based classification of gliomas, as well as the long time course of this disease, a thoughtful and comprehensive strategy to studying patient outcomes and devising methods of cognitive risk reduction is required.
Similar content being viewed by others
References
Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773
Wefel JS et al (2016) Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro Oncol 18(12):1656–1663
Noll KR et al (2015) Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro Oncol 17(4):580–587
Noll KR et al (2017) Relationships between neurocognitive functioning, mood, and quality of life in patients with temporal lobe glioma. Psychooncology 26(5):617–624
Derks J et al (2019) Understanding cognitive functioning in glioma patients: the relevance of IDH-mutation status and functional connectivity. Brain Behav 9(4):e01204
Stoecklein VM et al (2020) Resting-state fMRI detects alterations in whole brain connectivity related to tumor biology in glioma patients. Neuro Oncol 22(9):1388–1398
Nasreddine ZS et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699
Kesler SR et al (2016) The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neurooncol
Price SJ et al (2017) Less invasive phenotype found in Isocitrate dehydrogenase-mutated glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: a Diffusion-Tensor Imaging Study. Radiology 283(1):215–221
Jutten K et al (2019) Diffusion Tensor Imaging reveals Microstructural Heterogeneity of Normal-Appearing White Matter and related cognitive dysfunction in Glioma Patients. Front Oncol 9:536
Duffau H (2013) The huge plastic potential of adult brain and the role of connectomics: new insights provided by serial mappings in glioma surgery. Cortex 58:325–337
Duffau H, Denvil D, Capelle L (2002) Long term reshaping of language, sensory, and motor maps after glioma resection: a new parameter to integrate in the surgical strategy. J Neurol Neurosurg Psychiatry 72(4):511–516
Duffau H, Moritz-Gasser S, Mandonnet E (2014) A re-examination of neural basis of language processing: proposal of a dynamic hodotopical model from data provided by brain stimulation mapping during picture naming. Brain Lang 131:1–10
Duffau H (2022) A personalized longitudinal strategy in low-grade glioma patients: predicting oncological and neural interindividual variability and its changes over years to think one step ahead. J Pers Med 12(10)
Venkatesh HS et al (2019) Electrical and synaptic integration of glioma into neural circuits. Nature 573(7775):539–545
Venkataramani V et al (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573(7775):532–538
Chaytor N, Schmitter-Edgecombe M (2003) The ecological validity of neuropsychological tests: a review of the literature on everyday cognitive skills. Neuropsychol Rev 13(4):181–197
Collins C, Gehrke A, Feuerstein M (2013) Cognitive tasks challenging brain tumor survivors at work. J Occup Environ Med 55(12):1426–1430
NCCN. NCCN Clinical Practice Guidelines in Oncology - Central Nervous System Cancers (2022) [cited 2022 12/31/2022]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198
Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21(19):3557–3558
Racine CA et al (2015) Neurocognitive function in newly diagnosed low-grade glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery 77(3):371–379; discussion 379
Block CK et al (2017) Discriminating cognitive screening and cognitive testing from neuropsychological assessment: implications for professional practice. Clin Neuropsychol 31(3):487–500
Noll KR et al (2018) Neuropsychological practice in the oncology setting. Arch Clin Neuropsychol 33(3):344–353
Noll KR et al (2019) Monitoring of neurocognitive function in the care of patients with brain tumors. Curr Treat Options Neurol 21(7):33
Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5(2):89–95
Johnson DR et al (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 14(6):808–816
Meyers CA et al (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3):646–650
Noll KR, Sullaway CM, Wefel JS (2019) Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neurooncol 142(1):183–191
Baum KT et al (2017) Implementing guidelines: proposed definitions of neuropsychology services in pediatric oncology. Pediatr Blood Cancer 64(8)
Weitzner MA et al (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151–1161
Aaronson NK et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Zarrella GV et al (2021) Reliability and validity of a novel cognitive self-assessment tool for patients with cancer. Neurooncol Pract 8(6):691–698
Benton AL, Varney NR, Hamsher KD (1978) Visuospatial judgment. A clinical test. Arch Neurol 35(6):364–367
Wilson SM et al (2018) A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. PLoS ONE 13(2):e0192773
Benton A, Hanmsher K, Sivan A (1983) Multilingual aphasia examination. AJA Associates, Iowa City, IA
Wechsler D, Assessment P (2008) Wechsler Adult Intelligence Scale: WAIS-IV; Technical and Interpretive Manual. Pearson
Lezak M et al (2012) Neuropsychological assessment, 5th edn. Oxford University Press, New York
Benedict R et al (1998) Hopkins Verbal Learning Test - revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12:43–55
Benedict R (1997) Brief Visuospatial Memory Test-Revised. Psychological Assessment Resources, Odessa, FL
Sabsevitz DS et al (2020) Neuropsychologist’s role in the management of Brain Tumor Patients. Brain mapping: indications and techniques. Thieme
Parsons MW, Dietrich J (2021) Assessment and Management of cognitive symptoms in patients with brain tumors. Am Soc Clin Oncol Educ Book 41:e90–e99
Bookheimer S (2007) Pre-surgical language mapping with functional magnetic resonance imaging. Neuropsychol Rev 17(2):145–155
Mandonnet E et al (2015) Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery 76(4):382–389; discussion 389
Gehring K, Etzel SA, Lang C F., Wefel J (2011) Prediction of memory outcomes after resection of high-grade glioma (Abstract). Neurooncology 13:iii73
Gehring K, Etzel SA, Lang C F., Wefel J (2011) Prediction of language outcomes after resection of high-grade glioma (Abstract). Neurooncology 13:iii75
Noll KR et al (2015) Neurocognitive changes Associated with Surgical Resection of Left and right temporal lobe glioma. Neurosurgery 77(5):777–785
Jakola AS et al (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308(18):1881–1888
Delev D et al (2019) Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system. J Neurooncol 141(1):223–233
Tatum WO et al (2020) Detection of after-discharges during intraoperative functional brain mapping in awake brain tumor surgery using a novel high-density circular grid. Clin Neurophysiol 131(4):828–835
Aabedi AA et al (2021) Functional alterations in cortical processing of speech in glioma-infiltrated cortex. Proc Natl Acad Sci U S A 118(46)
Rivera-Rivera PA et al (2017) Cortical plasticity catalyzed by prehabilitation enables extensive resection of brain tumors in eloquent areas. J Neurosurg 126(4):1323–1333
Lundqvist A (2001) Neuropsychological aspects of driving characteristics. Brain Inj 15(11):981–994
Lai R et al (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62(3):451–456
Tallet AV et al (2012) Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment. Radiat Oncol 7:77
Crossen JR et al (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12(3):627–642
Douw L et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8(9):810–818
Klein M et al (2004) [Impaired cognitive functioning in low-grade glioma patients: relationship to tumor localisation, radiotherapy and the use of anticonvulsants]. Ned Tijdschr Geneeskd 148(44):2175–2180
Klein M et al (2021) Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033–26033. Neuro Oncol 23(5):803–811
Prabhu RS et al (2014) Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98 – 02. J Clin Oncol 32(6):535–541
Reijneveld JC et al (2016) Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17(11):1533–1542
Sherman JC et al (2016) Neurocognitive effects of proton radiation therapy in adults with low-grade glioma. J Neurooncol 126(1):157–164
Gorske T (2008) Therapeutic neuropsychological assessment: a humanistic model and case example. J Humanistic Psychol 48(3):320–339
Postal K, Armstrong K (2013) Feedback that sticks: the art of effectively communicating Neuropsychological Assessment results. Oxford University Press, New York
Gehring K et al (2010) Interventions for cognitive deficits in patients with a brain tumor: an update. Expert Rev Anticancer Ther 10(11):1779–1795
Ferguson RJ et al (2007) Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16(8):772–777
Noll KR et al (2018) Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract 5(3):184–193
Bergo E et al (2016) Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art. J BioMed Res Int 2016:11
Gehring K et al (2009) Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 27(22):3712–3722
van Lonkhuizen PJC et al (2019) Interventions for cognitive problems in adults with brain cancer: a narrative review. Eur J Cancer Care (Engl) 28(3):e13088
Coomans MB et al (2019) Treatment of cognitive deficits in brain tumour patients: current status and future directions. Curr Opin Oncol 31(6):540–547
van der Linden SD et al (2018) Feasibility of the evidence-based cognitive telerehabilitation program remind for patients with primary brain tumors. J Neurooncol 137(3):523–532
Yang S, Chun MH, Son YR (2014) Effect of virtual reality on cognitive dysfunction in patients with brain tumor. Ann Rehabil Med 38(6):726–733
Karschnia P, Parsons MW, Dietrich J (2019) Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol 20(2):e92–e102
Clinicaltrials.gov search of brain tumors and cognitive. Available from: https://clinicaltrials.gov
Author information
Authors and Affiliations
Contributions
MP and DS wrote and reviewed the manuscript. MP prepared the figures.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Parsons, M.W., Sabsevitz, D.S. Cognitive issues in patients with IDH mutant gliomas: from neuroscience to clinical neuropsychology. J Neurooncol 162, 525–533 (2023). https://doi.org/10.1007/s11060-023-04289-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-023-04289-4